ESMO 2022 Conference Coverage


 

ESMO 2022 on the Phase III ERMES Study: FOLFIRI/Cetuximab vs. FOLFIRI/Cetuximab Followed by Cetuximab Alone in 1L Therapy of RAS and BRAF Wild-Type mCRC

219 views
September 27, 2022
Comments 0
Login to view comments. Click here to Login